finasteride/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Depletes 17beta-hydroxy-5alpha-androstan-3-one
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Before intervention, PSA and serum steroid hormone levels were not statistically different between groups; after intervention, the finasteride group had significantly lower PSA (3.2 ng/mL versus 5.2 ng/mL; P < 0.001) and DHT levels (10 ng/dL versus 27 ng/dL; P < 0.001) and a significantly higher testosterone level (382 ng/dL versus 327 ng/dL; P = 0.04) than the placebo group.”
Quoted verbatim from Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.. - Study
- RCT
- Dose
- 5 mg daily
- Population
- Men with clinically organ-confined prostate cancer randomized to finasteride or placebo for 4-6 weeks before prostatectomy; serum DHT
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.2016PMID:27322462Permalink
Keep reading
- Everything the graph holds on finasteride
- Every compound studied against 17beta-hydroxy-5alpha-androstan-3-one
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45HJ6FDW1XPWB2ZS95FBH0X